Huvepharma extends deadline after getting ratings
Bankers now hope to complete a €275m acquisition loan for Bulgarian drugs firm Huvepharma this week after extending the deadline to wait for Moody's and Standard & Poor's to provide ratings.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: